deltatrials
Terminated PHASE2 INTERVENTIONAL NCT00435578

Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma

An Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of Glufosfamide in the Treatment of Patients With Recurrent Sensitive Small Cell Lung Carcinoma

Sponsor: Threshold Pharmaceuticals

Conditions Carcinoma, Small Cell Lung
Interventions Glufosfamide
Last updated: Apr 28, 2009 Started: Feb 28, 2007 Primary completion: Nov 30, 2007 Completion: Nov 30, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Threshold Pharmaceuticals

More terminations from Threshold Pharmaceuticals

Other Carcinoma, Small Cell Lung trials with similar outcome

Browse all Carcinoma, Small Cell Lung trials

Listed as NCT00435578, this PHASE2 trial focuses on Carcinoma, Small Cell Lung and remains terminated or withdrawn. Sponsored by Threshold Pharmaceuticals, it has been updated 0 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

No change history available.

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Threshold Pharmaceuticals
Data source: Threshold Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations